Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Recruiting now · Phase 2
Conditions studied: Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei
In brief
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
Key facts
- Study ID
- NCT07693452
- Run by
- University of California, Irvine
- People needed
- 15
- Starts
- 2026-06-18
- Expected to finish
- 2029-07-01
- Last updated by the study team
- 2026-07-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.